BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 25891354)

  • 21. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
    Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postablative 131I SPECT/CT Is Much More Sensitive Than Cervical Ultrasonography for the Detection of Thyroid Remnants in Patients After Total Thyroidectomy for Differentiated Thyroid Cancer.
    Bulzacka I; Makarewicz J
    Clin Nucl Med; 2020 Dec; 45(12):948-953. PubMed ID: 32969911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The differential diagnosis of central compartment radioactive iodine uptake after thyroidectomy: anatomic and surgical considerations.
    Dos Reis LL; Mehra S; Scherl S; Clain J; Machac J; Urken ML
    Endocr Pract; 2014 Aug; 20(8):832-8. PubMed ID: 24793917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pyramidal lobe decreases endogenous TSH stimulation without impact on radio-iodine therapy outcome in patients with differentiated thyroid cancer.
    Sawicka-Gutaj N; Klimowicz A; Sowinski J; Oleksa R; Gryczynska M; Wyszomirska A; Czarnywojtek A; Ruchala M
    Ann Endocrinol (Paris); 2014 Jul; 75(3):141-7. PubMed ID: 24997767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
    Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
    Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?
    Cailleux AF; Baudin E; Travagli JP; Ricard M; Schlumberger M
    J Clin Endocrinol Metab; 2000 Jan; 85(1):175-8. PubMed ID: 10634383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of thyroglobulin measurements in fine-needle aspirates of space occupying lesions in the thyroid bed after thyroid cancer operations.
    Suh YJ; Son EJ; Moon HJ; Kim EK; Han KH; Kwak JY
    Thyroid; 2013 Mar; 23(3):280-8. PubMed ID: 22950788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging.
    Spanu A; Solinas ME; Chessa F; Sanna D; Nuvoli S; Madeddu G
    J Nucl Med; 2009 Feb; 50(2):184-90. PubMed ID: 19164225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer.
    Iwano S; Ito S; Kamiya S; Ito R; Kato K; Naganawa S
    Nagoya J Med Sci; 2020 May; 82(2):205-215. PubMed ID: 32581401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
    Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
    Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of surgical completeness in endoscopic thyroidectomy compared with open thyroidectomy with regard to remnant ablation.
    Im HJ; Koo do H; Paeng JC; Lee KE; Chung YS; Lim I; Lee DS; Chung JK; Youn YK
    Clin Nucl Med; 2012 Feb; 37(2):148-51. PubMed ID: 22228337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
    Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Applying postoperative radioiodine therapy before 3 months seems to decrease ablation success in patients with differentiated thyroid carcinoma.
    Özdoğan Ö; Aksu A; Doğan E; Bülbül O; Güray Durak M; Sevinç Aİ; Bayraktar F; İkiz AÖ
    Ann Nucl Med; 2021 Feb; 35(2):223-231. PubMed ID: 33389664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical significance of remnant thyroid tissue in thyroidectomized differentiated thyroid cancer patients on
    Wang F; Nie H; Li W; Zhang R; Li W
    BMC Med Imaging; 2021 May; 21(1):78. PubMed ID: 33964885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients.
    Tatar FA; Morita E; Ituarte PH; Cavalieri RR; Duh QY; Price DC; Siperstein AE; Clark OH
    World J Surg; 2001 Jun; 25(6):718-22. PubMed ID: 11376405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
    Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
    Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL; Kloos RT
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin?
    Rosario PW; Mourão GF; dos Santos JB; Calsolari MR
    Thyroid; 2014 Mar; 24(3):533-6. PubMed ID: 24067080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy of radioiodine remnant ablation for differentiated thyroid carcinoma patients with an incomplete thyroidectomy.
    Hfu H; Ma C; Li J; Feng F; Wu S; Ye Z; Wang H
    Q J Nucl Med Mol Imaging; 2016 Sep; 60(3):280-4. PubMed ID: 25192307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.